close and back to page

Latest News

Latest News

Abbott, North West London Pathology Partner For Diagnostics Products and Services

The companies signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables.

North West London Pathology (NWLP), hosted by Imperial College Healthcare NHS Trust, and Abbott (No. 10 on the DiversityInc Top 50 Companies list) announced that they signed a $252 million managed equipment services contract for the supply of all analytical equipment and consumables, including Abbott's Alinity ci and Alinity h series diagnostics instruments as well as their professional services and informatics solutions known as AlinIQ.


The contract was the subject of a detailed and competitive procurement process conducted by NWLP. Imperial College Healthcare NHS Trust, Chelsea and Westminster NHS Foundation Trust and the Hillingdon Hospitals NHS Foundation Trust consolidated their pathology services into NWLP earlier this year to better manage demand, standardize operations, improve value for money and make use of new technologies.

Stephen Snewin, managing director of NWLP, said: "NWLP aims to provide an innovative and sustainable pathology service which delivers outstanding quality for our patients and clinicians. After a highly competitive process involving multiple diagnostic equipment manufacturers, NWLP is extremely excited to be working with Abbott, which supports our vision of increased efficiency and transformation across six major sites in North West London using the latest technology."

The partnership is expected to manage 26 million tests per year and currently holds 6 percent of the total pathology market in the UK.

"Abbott is delighted to provide NWLP with personalized Alinity and AlinIQ solutions to help them navigate the challenges of an evolving healthcare system," said Mike Clayton, managing director, Northern Europe, for Abbott's diagnostics business. "Through our partnership, we will equip NWLP to help maximize productivity, drive faster delivery of test results and provide the critical information needed for clinical decisions – with the goal of helping the Trust improve patient outcomes."

The hospitals included within this partnership are: Imperial College Healthcare NHS Trust, which comprises St Mary's Hospital, Charing Cross Hospital, Hammersmith Hospital, Queen Charlotte and Chelsea Hospital and the Western Eye Hospital; Chelsea & Westminster Hospital Foundation Trust, which comprises Chelsea & Westminster Hospital and West Middlesex University Hospital; and Hillingdon Hospitals NHS Foundation Trust, which comprises Hillingdon Hospital and Mount Vernon Hospital.

Abbott: Top Internship for Healthcare and Tech

Interns have spoken: Abbott is the top college internship program for healthcare and tech & engineering.

Originally Published by Abbott.

Abbott recognizes the need to develop its future leaders early, and has been named the top healthcare and tech & engineering internship program by Vault.

Read More Show Less

New Study Shows Abbott's Novel Diagnostic Test Could Help Rule Out Heart Attacks Earlier

Preliminary research indicates that a diagnostic test currently in development, that is done at the patient's side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack .

Originally Published by Abbott.

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data, published online in JAMA Cardiology, found a new blood test under development that is done right at the patient's side in as little as 15 minutes could identify nearly three-fifths (56.7 percent) of people at low-risk of experiencing a heart attack, similar to the results of a High Sensitive Troponin-I blood test done in the laboratory setting.

Read More Show Less

Abbott: Partnering for a Healthier Future

Abbott supports the First Ladies of Africa in the fight to end AIDS in children and keep mothers healthy.

Originally Published by Abbott.

In countries around the world, Abbott is working across its businesses and in partnerships with others to create healthier futures for families. One example: since 2014, Abbott's diagnostics business has supported the work of the Organization of African First Ladies Against HIV/AIDS (OAFLA – pictured above) to fight the AIDS epidemic in Africa, particularly among pregnant women and children – who are among the most vulnerable populations impacted by the disease.

At an OAFLA meeting on the sidelines of the UN General Assembly in New York City, Abbott and several other organizations are being recognized by OAFLA for longstanding partnership and support, including public-private partnerships that bring together technical, financial and other resources to focus on a global health challenge such as HIV/AIDS.

Read More Show Less

Abbott: DRG Stimulator, A Life Changing Technology for Chronic Pain.

The new technological DRG therapy may be the key to easing daily tasks for those with chronic pain.

Originally Published by Abbott.

Living with chronic pain affects not just your body but also your mind. It can make getting around and getting along equally difficult.

But with innovation in health technology comes hope. Abbott has developed a new device found to be more effective than traditional therapy at relieving chronic pain.

Read More Show Less

Abbott: Expediting Blood Testing With i-Stat

The portable, handheld i-STAT Alinity delivers quick blood test results anywhere you are.

Originally Published by Abbott.

Every day, countless blood samples are tested all around the world for one purpose: to help diagnose and treat medical conditions. From the couple eagerly awaiting the results of a pregnancy blood test to a worried cancer patient hoping for more answers, diagnostic blood tests give vital insight into what's happening underneath the skin.

Read More Show Less

Abbott: Freestyle Libre 14 Day, Now FDA Approved

Abbott's flash glucose monitor now FDA-approved for two weeks of use in U.S. between sensor changes.

Originally Published by Abbott.

The U.S. Food and Drug Administration has approved FreeStyle Libre 14 day— Abbott's revolutionary continuous glucose monitoring system. In the U.S., you can wear the sensor up to 14 days with high accuracy.

Read More Show Less

At Abbott, You Look Like An Engineer

Decades before #ILookLikeAnEngineer, Abbott paved the way for a non-profit dedicated to diversity in STEM.

Originally Published by Abbott.

#ILookLikeAnEngineer.

Remember this? A few years ago, a young software engineer was featured in a recruiting advertisement, only to be accused of not being an actual engineer. Frustrated with the assertion, Isis Wenger started a movement to break the stereotype of what an engineer should look like.

Read More Show Less

Abbott Receives FDA Approval for Next-Generation MitraClip Device to Treat People with Leaky Heart Valves

MitraClip is the gold-standard minimally invasive alternative to open-heart surgery for people needing mitral valve repair.

Originally Published by Abbott.

Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for a next-generation version of its leading MitraClip® heart valve repair device used to repair a leaky mitral valve without open-heart surgery. The transcatheter clip-based therapy, now on a third generation of product innovations, has been used to treat more than 65,000 patients worldwide over the last ten years.

Read More Show Less